We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Human Genome Sciences announced that the results of a Phase II clinical trial
demonstrate that HGS-ETR1 (mapatumumab) is well-tolerated and can be administered
safely in patients with advanced non-small cell lung cancer (NSCLC).
Results of Ligand Pharmaceuticals' two pivotal Phase III studies (SPIRIT I &
SPIRIT II) of Targretin (bexarotene) capsules in front-line combination therapy
with standard chemotherapy to treat advanced non-small cell lung cancer (NSCLC)
were presented at the 11th World Conference on Lung Cancer in Barcelona, Spain.
Cell Genesys has initiated a second multicenter Phase III clinical trial of
its GVAX vaccine for prostate cancer in patients with metastatic hormone-refractory
prostate cancer.
The FDA has granted final approval to Alpharma's abbreviated new drug application
for glyburide/metformin HCl tablets in 1.25-mg/250-mg, 2.5-mg/500-mg and 5-mg/500-mg
dosage forms.
The FDA has approved once-daily antibiotic Avelox (moxifloxacin HCl) for the
treatment of complicated skin and skin structure infections (cSSSI) in adults
caused by methicillin-susceptible staphylococcus aureus, escherichia coli, klebsiella
pneumoniae or enterobacter cloacae.
Pfizer has terminated the development of two drug candidates in its pipeline,
one targeted at HIV/AIDS and another intended to treat asthma and chronic obstructive
pulmonary disease.
Gilead Sciences announced that data through 144 weeks supporting the efficacy
and tolerability of its oral antiviral drug Hepsera (adefovir dipivoxil) in
patients chronically infected with hepatitis B "e" antigen-negative
(HBeAg-negative) were published in the June 30 edition of The New England Journal
of Medicine (NEJM).
Hollis-Eden Pharmaceuticals announced the FDA has determined that it is safe
to proceed with Phase I human clinical trials with its investigational compound
Neumune in the U.S. pursuant to an investigational new drug application it recently
filed with the agency.